Trial Profile
A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers iPRIME.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms iPRIME
- 24 Nov 2021 Planned End Date changed from 30 May 2022 to 30 Sep 2023.
- 24 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2020 Status changed from not yet recruiting to recruiting.